Page 62 - 76_02

ANDRÉS R. ALCÁNTARA LEÓN Y COLS. AN. R. ACAD. NAC. FARM.

14. Ariens, E. J. (1984) Stereochemistry: a basis for sophisticated nonsense in
pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26:
663-668.

15. Eichelbaum, M. & Gross, A. S. (1996) Stereochemical aspects of drug action
and disposition. Adv. Drug Res. 28: 1-64.

16. Caldwell, J. & Leonard, B. E. (2001) The enantiomer debate: realising the
potential of enantiomers in pharmacology. Hum. Psychopharmacol. Clin. Exp.
16 (Suppl. 2): S65-S107.

17. Stinson, S. C. (2001) Chiral chemistry. Chem. Eng. News. 79: 45-56.
18. Agranat, I.; Caner, H. & Caldwell, J. (2002) Putting Chirality To Work: The

Strategy of Chiral Switches. Nature Reviews Drug Discovery. 1: 753-768.
19. Wrotnowski, C. (1997) Unexpected niche applications for industrial enzymes

drives market growth. Gen. Eng. News. 1: 14-30.
20. Kazlauskas, R. J. (2005) Enhancing catalytic promiscuity for biocatalysis. Curr.

Op. Chem. Biol. 9: 195-201.
21. Ireland, C., et al. (1997) Lobucavir: antiviral. Drugs Future. 22: 359.
22. Hanson, R., et al. (2000) Regioselective enzymatic aminoacylation of lobucavir

to give an intermediate for lobucavir prodrug. Bioorg. Med. Chem. 8: 2681.
23. Zhang, J., et al. (1995) Bioconversion of indene to trans-2S, lS-bromoindanol

and 1S,2R-indene oxide by a bromoperoxidase/dehydrogenase preparation
from Curvularia protuberata MF5400. J. Ferment. Bioeng. 80: 244.
24. Holton, R., et al. (1995) Semisynthesis of taxol and taxotere, in Taxol Science
and Application, Suffness, M., Ed., CRC Press, New York.
25. Baldini. E., et al. (2004) Multicenter randomized phase III trial of Epirubicin
plus Paclitaxel vs. Epirubicin followed by Paclitaxel in metastatic breast can-
cer patients: focus on cardiac safety. Br. J. Cancer. 91: 45.
26. Patel, R. N. (1995) Tour de paclitaxel: biocatalysis for semisynthesis. Ann.
Rev. Microbiol. 98: 361.
27. Patel, R. N., et al. (1994) Enzymic preparation of (3R-cis)-3-(acetyloxy)-
4-phenyl-2-azetidinone: a taxol side-chain synthon. Biotech. Appl Biochem.
20: 23.
28. Baloglu, E. & Kingston, D. (1999) The taxane diterpenoids. J. Nat. Prod. 62:
1068.
29. Rose, W. (2001) Preclinical pharmacology of BMS-275183, an orally active
taxane. Clin. Cancer Res. 7: 2016.
30. Holton, R.; Nadizadeh, H. & Beidiger, R. (1993) Preparation of substituted
taxanes as antitumor agents, Eur. Patent Appl. 17 pp. EP 534708 Al 19930331
CAN 119:49693 AN 1993:449693.
31. Umezawa, H., et al. (1981) Structure of an antitumor antibiotic. Spergualin.
J. Antibiot. 34: 1622.
32. Umeda, Y., et al. (1987) Synthesis and antitumor activity of spergualin analo-
gues, III: novel method for synthesis of optically active 15-deoxyspergualin
and 15-deoxy-ll-O-methylspergualin. J. Antibiol. 40: 1316.
33. Patel, R. N.; Banerjee, A. & Szarka, L. J. (1997) Stereoselective acetylation of
racemic 7-[N,N´-bis(benziloxicarbonil)-N-(guanidinoheptanoil)]-”-hidroxi-glici-
na. Tetrahedron Asymmetry. 8: 1767.

300